| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Microtubules (via a mechanism distinct from direct tubulin binding; the specific cellular binding site is not identified in this paper). [2]
|
|---|---|
| ln Vitro |
Taccalonolide B inhibits the proliferation of drug-sensitive SK-OV-3 ovarian cancer cells with an IC50 of 208 ± 14 nM. In Pgp-overexpressing SK-OV-3/MDR-1-6/6 cells, the IC50 is 2547 ± 282 nM, resulting in a relative resistance value of 12.2, indicating that Taccalonolide B is significantly better than paclitaxel (860-fold resistance) at circumventing Pgp-mediated resistance. [2]
In HEK293 cells transfected with MRP7 (HEK-MRP7-C17 and HEK-MRP7-C18) compared to vector-transfected control (HEK-pcDNA3), Taccalonolide B does not show substantial resistance. The IC50 values are: HEK-pcDNA3 = 1.66 ± 0.52 µM; HEK-MRP7-C17 = 1.30 ± 0.37 µM (relative resistance 0.78); HEK-MRP7-C18 = 2.07 ± 0.33 µM (relative resistance 1.3). These data indicate that Taccalonolide B circumvents MRP7-mediated drug resistance. [2] Using an isogenic HeLa cell line that ectopically expresses the βIII-tubulin isotype (wild-type βIII cells), Taccalonolide B shows greater sensitivity compared to parental HeLa cells. The IC50 in HeLa cells is 190 ± 31 nM, while in wild-type βIII cells it is 120 ± 8 nM (relative resistance 0.6). In contrast, paclitaxel shows 4.7-fold resistance (IC50: HeLa = 1.63 ± 0.15 nM; wild-type βIII = 7.73 ± 0.23 nM), docetaxel shows 6.8-fold resistance, and epothilone B shows 2.3-fold resistance in the βIII-expressing cells. [2] |
| Cell Assay |
Antiproliferative effects were evaluated using the sulforhodamine B (SRB) assay. Cells were seeded and treated with various drug concentrations for 48 hours. The concentration causing 50% inhibition of proliferation (IC50) was calculated from graphs of at least seven drug concentrations spanning the entire range of growth inhibition. Experiments were performed three independent times, each using triplicate points. This assay was used for SK-OV-3, SK-OV-3/MDR-1-6/6, HeLa, and wild-type βIII cell lines to determine IC50 values for Taccalonolide B and other compounds. [2]
For MRP7-transfected HEK293 cells, a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt/phenazine methosulfate (MTS) microtiter plate assay was used. Cells were seeded at 3,000 cells per well in 96-well plates, treated with various drug concentrations the next day, and colorimetric analysis was performed after 72 hours of growth in the presence of drug. This assay was used to assess the sensitivity of HEK-pcDNA3, HEK-MRP7-C17, and HEK-MRP7-C18 cells to Taccalonolide B. [2] Immunoblot analysis was performed to confirm βIII-tubulin expression in wild-type βIII cells. Cellular protein was isolated, separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with monoclonal β-tubulin isotype-specific antibodies. This confirmed that βI-, βII-, and βIV-tubulins were expressed at equivalent levels in HeLa and wild-type βIII cells, and βIII-tubulin was detected only in the wild-type βIII cells. [2] Indirect immunofluorescence was used to visualize mitotic spindles containing βIII-tubulin (green) or Aurora A (red) with nuclear staining (blue) in HeLa and wild-type βIII cells. This confirmed that βIII-tubulin was correctly localized to the mitotic spindle in the expressing cells. [2] |
| References | |
| Additional Infomation |
Reports indicate that konjac plants (Tacca chantrieri) and Tacca plantaginea contain konjac lactone B, and relevant data are available for reference.
Taccalonolide B is generated from Taccalonolide A via mild base hydrolysis that removes the acetyl group at the C15 position. This chemical modification significantly increases potency, as evidenced by at least a 3-fold decrease in the IC50 value of Taccalonolide B compared to Taccalonolide A in nearly every cell line tested. [2] Taccalonolide B, along with other taccalonolides, represents a unique class of microtubule stabilizers that do not bind directly to tubulin. Their ability to circumvent Pgp-, MRP7-, and βIII-tubulin-mediated resistance suggests they may have advantages over taxanes in treating drug-resistant tumors. [2] |
| Molecular Formula |
C34H44O13
|
|---|---|
| Molecular Weight |
660.7054
|
| Exact Mass |
660.278
|
| CAS # |
108885-69-4
|
| PubChem CID |
56662029
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
775.9±60.0 °C at 760 mmHg
|
| Flash Point |
242.4±26.4 °C
|
| Vapour Pressure |
0.0±6.0 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
1.88
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
47
|
| Complexity |
1510
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
C[C@@H]1C=C2[C@@]([C@H]3[C@H]1[C@@]4([C@@H]([C@H]3O)[C@H]5[C@H]([C@@H]([C@@H]4OC(=O)C)OC(=O)C)[C@@]6([C@H](C[C@H]7[C@@H]([C@@H]6OC(=O)C)O7)C(=O)[C@@H]5O)C)C)([C@](C(=O)O2)(C)O)C
|
| InChi Key |
FFQOXBQSZPYHSA-MPOUNFKCSA-N
|
| InChi Code |
InChI=1S/C34H44O13/c1-11-9-17-33(7,34(8,42)30(41)47-17)22-19(11)32(6)20(25(22)40)18-21(27(43-12(2)35)29(32)45-14(4)37)31(5)15(23(38)24(18)39)10-16-26(46-16)28(31)44-13(3)36/h9,11,15-16,18-22,24-29,39-40,42H,10H2,1-8H3/t11-,15-,16+,18+,19+,20-,21-,22+,24-,25-,26+,27+,28+,29+,31+,32-,33+,34-/m1/s1
|
| Chemical Name |
[(1S,2S,3R,5S,7S,9S,10R,11R,12S,13S,14R,15R,16S,17S,22S,23S,24R,25R)-10,14-diacetyloxy-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.02,12.05,11.07,9.016,24.019,23]pentacos-18-en-13-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5135 mL | 7.5676 mL | 15.1352 mL | |
| 5 mM | 0.3027 mL | 1.5135 mL | 3.0270 mL | |
| 10 mM | 0.1514 mL | 0.7568 mL | 1.5135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
